UroGen's ZUSDURI Gains Permanent Billing Code, Streamlining Access
Event summary
- UroGen Pharma’s ZUSDURI (mitomycin) for intravesical solution now has a permanent Healthcare Common Procedure Coding System Level II J Code (J9282) effective January 1, 2026.
- The new J Code is expected to simplify billing and reimbursement processes for ZUSDURI treatment across hospital and physician settings.
- ZUSDURI is the first and only FDA-approved therapy for adults with recurrent low-grade intermediate-risk non–muscle invasive bladder cancer (LG-IR-NMIBC).
- Approximately 82,000 people in the U.S. are affected by LG-IR-NMIBC annually, with roughly 59,000 experiencing recurrence.
The big picture
The permanent J Code represents a significant win for UroGen, addressing a key barrier to adoption for ZUSDURI. While seemingly technical, this change directly impacts patient access and revenue generation for a therapy targeting a niche but recurring condition affecting tens of thousands of Americans. The move highlights the ongoing importance of navigating the complex reimbursement landscape in the biotech sector, where administrative hurdles can significantly impact commercial success.
What we're watching
- Adoption Rate
- The speed at which treatment centers incorporate J9282 into their billing practices will determine the immediate impact on ZUSDURI utilization and revenue.
- Payer Response
- How individual payers adapt their coverage policies following the J Code implementation will be crucial in ensuring broad and sustained patient access.
- Clinical Data
- Ongoing clinical trials and real-world data collection will be critical to solidify ZUSDURI's long-term value proposition and support continued reimbursement.
Related topics